Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis

George Richard Thompson, James S. Lewis, David E. Nix, Thomas F. Patterson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Coccidioidomycosis remains a significant clinical problem with substantial morbidity and mortality. The vast majority of infections are asymptomatic and the need for early primary therapy remains controversial. The use of triazole antifungals has improved tolerability of therapy but concerns about acute and long-term toxicities among available agents limit their use. In addition, recent findings of decreased in vitro fluconazole susceptibility to as many as 37% of Coccidioides spp. isolates raises concerns regarding optimal therapy for these infections as fluconazole is commonly used for therapy including central nervous system disease. Thus, new agents from novel antifungal classes are currently in preclinical and clinical development aimed at reducing toxicity and improving outcomes of these serious infections.

Original languageEnglish (US)
Pages (from-to)S76-S84
JournalMedical Mycology
Volume57
Issue number1
DOIs
StatePublished - Feb 1 2019

Fingerprint

Coccidioidomycosis
Fluconazole
Pharmacology
Coccidioides
Asymptomatic Infections
Triazoles
Antifungal Agents
Central Nervous System Diseases
Secondary Prevention
Infection
Therapeutics
Morbidity
Mortality
Direction compound

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis. / Thompson, George Richard; Lewis, James S.; Nix, David E.; Patterson, Thomas F.

In: Medical Mycology, Vol. 57, No. 1, 01.02.2019, p. S76-S84.

Research output: Contribution to journalArticle

Thompson, George Richard ; Lewis, James S. ; Nix, David E. ; Patterson, Thomas F. / Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis. In: Medical Mycology. 2019 ; Vol. 57, No. 1. pp. S76-S84.
@article{6b6231b92b2f44cf8fe82abac308c3c8,
title = "Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis",
abstract = "Coccidioidomycosis remains a significant clinical problem with substantial morbidity and mortality. The vast majority of infections are asymptomatic and the need for early primary therapy remains controversial. The use of triazole antifungals has improved tolerability of therapy but concerns about acute and long-term toxicities among available agents limit their use. In addition, recent findings of decreased in vitro fluconazole susceptibility to as many as 37{\%} of Coccidioides spp. isolates raises concerns regarding optimal therapy for these infections as fluconazole is commonly used for therapy including central nervous system disease. Thus, new agents from novel antifungal classes are currently in preclinical and clinical development aimed at reducing toxicity and improving outcomes of these serious infections.",
author = "Thompson, {George Richard} and Lewis, {James S.} and Nix, {David E.} and Patterson, {Thomas F.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1093/mmy/myy029",
language = "English (US)",
volume = "57",
pages = "S76--S84",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis

AU - Thompson, George Richard

AU - Lewis, James S.

AU - Nix, David E.

AU - Patterson, Thomas F.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Coccidioidomycosis remains a significant clinical problem with substantial morbidity and mortality. The vast majority of infections are asymptomatic and the need for early primary therapy remains controversial. The use of triazole antifungals has improved tolerability of therapy but concerns about acute and long-term toxicities among available agents limit their use. In addition, recent findings of decreased in vitro fluconazole susceptibility to as many as 37% of Coccidioides spp. isolates raises concerns regarding optimal therapy for these infections as fluconazole is commonly used for therapy including central nervous system disease. Thus, new agents from novel antifungal classes are currently in preclinical and clinical development aimed at reducing toxicity and improving outcomes of these serious infections.

AB - Coccidioidomycosis remains a significant clinical problem with substantial morbidity and mortality. The vast majority of infections are asymptomatic and the need for early primary therapy remains controversial. The use of triazole antifungals has improved tolerability of therapy but concerns about acute and long-term toxicities among available agents limit their use. In addition, recent findings of decreased in vitro fluconazole susceptibility to as many as 37% of Coccidioides spp. isolates raises concerns regarding optimal therapy for these infections as fluconazole is commonly used for therapy including central nervous system disease. Thus, new agents from novel antifungal classes are currently in preclinical and clinical development aimed at reducing toxicity and improving outcomes of these serious infections.

UR - http://www.scopus.com/inward/record.url?scp=85060650260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060650260&partnerID=8YFLogxK

U2 - 10.1093/mmy/myy029

DO - 10.1093/mmy/myy029

M3 - Article

C2 - 30690601

AN - SCOPUS:85060650260

VL - 57

SP - S76-S84

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 1

ER -